ArticleACG case reports journal2026
Sustained Remission Following Limited Dupilumab Exposure in Refractory Eosinophilic Esophagitis.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic esophagitis (EoE) is a type 2 immune-mediated esophageal disorder that can be refractory to standard therapy. We present a case of a 49-year-old woman with asthma, chronic sinusitis, and nasal polyposis diagnosed with EoE refractory to proton pump inhibitors, dietary modification, and swallowed topical corticosteroids. She was treated with dupilumab in 2023 but discontinued it after 3 months due to side effects. Subsequent esophagogastroduodenoscopies demonstrated sustained histologic and endoscopic remission up to October 2025 (26 months later), after which recurrence of disease was confirmed. This case highlights 2-year sustained remission following limited exposure to dupilumab in refractory EoE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.